Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KYMR Kymera Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KYMR
Price (delayed)
$30.07
Market cap
$1.95B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
$1.91B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's quick ratio has surged by 58% YoY but it has decreased by 13% QoQ
KYMR's net income has dropped by 52% year-on-year and by 34% since the previous quarter
KYMR's gross profit is down by 46% since the previous quarter and by 40% year-on-year
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
64.94M
Market cap
$1.95B
Enterprise value
$1.91B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.33
Price to sales (P/S)
47.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.67
Revenue
$47.07M
Gross profit
$47.07M
Operating income
-$261.64M
Net income
-$223.86M
EBIT
-$223.61M
EBITDA
-$216.24M
Free cash flow
-$207.34M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.76
Book value per share
$12.9
Revenue per share
$0.63
TBVPS
$13.03
Total assets
$978.04M
Total liabilities
$142.42M
Debt
$87.76M
Equity
$835.62M
Working capital
$442.5M
Debt to equity
0.11
Current ratio
7.53
Quick ratio
7.3
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-459.4%
Gross margin
100%
Net margin
-475.6%
Operating margin
-555.8%
Return on assets
-24.2%
Return on equity
-28.7%
Return on invested capital
-26.4%
Return on capital employed
-24.6%
Return on sales
-475%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
-2.27%
1 week
-14.77%
1 month
25.55%
1 year
-22.12%
YTD
-25.25%
QTD
9.86%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$47.07M
Gross profit
$47.07M
Operating income
-$261.64M
Net income
-$223.86M
Gross margin
100%
Net margin
-475.6%
The operating margin has plunged by 164% YoY and by 143% from the previous quarter
KYMR's net margin has dropped by 154% year-on-year and by 149% since the previous quarter
The company's operating income has shrunk by 58% YoY and by 31% QoQ
KYMR's net income has dropped by 52% year-on-year and by 34% since the previous quarter
Price vs fundamentals
How does KYMR's price correlate with its fundamentals
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
2.33
P/S
47.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.67
The company's EPS fell by 27% QoQ and by 18% YoY
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
The stock's price to book (P/B) is 47% less than its 5-year quarterly average of 4.4 and 25% less than its last 4 quarters average of 3.1
The price to sales (P/S) is 48% higher than the 5-year quarterly average of 32.5 and 16% higher than the last 4 quarters average of 41.4
KYMR's revenue is down by 46% from the previous quarter and by 40% YoY
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales has shrunk by 154% YoY and by 149% QoQ
KYMR's return on assets is down by 19% since the previous quarter but it is up by 4.3% year-on-year
The company's return on equity rose by 18% YoY but it fell by 15% QoQ
The return on invested capital has declined by 17% since the previous quarter but it has grown by 8% year-on-year
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total assets has soared by 70% YoY but it has contracted by 5% from the previous quarter
The current ratio has surged by 59% year-on-year but it has declined by 12% since the previous quarter
KYMR's debt is 89% smaller than its equity
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 48% YoY but it has increased by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.